Pharmaceutical Company
Appears in 6 stories
Defending Fluzone High-Dose franchise against mRNA entrants
For 80 years, flu vaccines grew in chicken eggs — a process effective against roughly 40% of infections in good years. On May 8, the New England Journal of Medicine published Moderna's Phase 3 data: mRNA-1010 reduced influenza illness by 26.6% more than a standard shot in 40,805 adults aged 50 and older. Moderna's stock rose 16% that day.
Updated May 31
Running Phase I/II clinical trial for mRNA acne vaccine
Nearly a billion people worldwide have acne, and for decades, the best medicine could offer was topical creams that irritate skin, antibiotics that breed resistance, or a powerful drug — isotretinoin — that causes birth defects. On December 5, 2023, researchers at UC San Diego published a finding that reframes the problem: the bacterium living on every human face produces two versions of the same enzyme. Which version dominates determines whether skin stays clear or breaks out.
Updated May 30
Co-developer and international marketer of Dupixent; projects sales reaching approximately $24 billion by 2030
Dupixent was approved for severe eczema in 2017 as a one-disease drug. Nine years later, it's approved for nine conditions, with the latest approval (February 24, 2026) covering allergic fungal rhinosinusitis (AFRS) — which previously had no approved treatment — and reducing the need for additional surgeries and steroid courses by 92% in trials.
Updated May 29
Developing rilzabrutinib across multiple autoimmune indications
For 50,000 Americans with warm autoimmune hemolytic anemia, there's never been a disease-specific treatment. On February 9, 2026, the FDA granted breakthrough therapy designation to rilzabrutinib—the first BTK inhibitor to reach this milestone for the condition—signaling it may offer substantial improvement over existing therapies.
Updated May 27
Seeking FDA guidance after tolebrutinib rejection
The FDA rejected Sanofi's tolebrutinib for progressive MS on December 28, 2025—a crushing blow for a drug that had won Breakthrough Therapy status and became the first BTK inhibitor approved anywhere in the world. Meanwhile, Roche's rival drug fenebrutinib is racing toward approval after strong Phase 3 results, and Merck's evobrutinib crashed out entirely. Three pharma giants bet billions that brain-penetrating BTK inhibitors could finally slow the relentless neurodegeneration that leaves MS patients in wheelchairs, and only one looks likely to reach the finish line first.
Updated May 16
Acquiring Dynavax to strengthen adult vaccine portfolio
Sanofi dropped $2.2 billion on December 24, 2025 to acquire Dynavax, a California biotech with a two-dose hepatitis B vaccine and a shingles vaccine in development. The 39% premium signals desperation in a market projected to hit $37.2 billion by 2033, driven by aging populations; the deal is expected to close in Q1 2026 pending Hart-Scott-Rodino antitrust clearance.[1] By 2050, 2.1 billion people will be over 60, triple the population over 80.
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
